Eyenovia proposes public stock offering

Eyenovia will offer and sell shares of its common stock in an underwritten public offering, using the proceeds to fund its MicroProst and MicroPine clinical studies, the company announced.

The underwriters are expected to be granted a 30-day option to purchase an additional 15% of the shares to be sold in the offering, which is subject to market and other conditions, according to a press release.

Eyenovia’s MicroProst, a treatment candidate for chronic angle closure glaucoma, open-angle glaucoma and ocular hypertension, and its myopia treatment candidate MicroPine are both in phase 3 development.

Oppenheimer & Co. Inc. is the offering’s sole book-running manager, with Ladenburg Thalmann & Co. Inc. acting as lead manager, the release said.

 

 

 

Eyenovia will offer and sell shares of its common stock in an underwritten public offering, using the proceeds to fund its MicroProst and MicroPine clinical studies, the company announced.

The underwriters are expected to be granted a 30-day option to purchase an additional 15% of the shares to be sold in the offering, which is subject to market and other conditions, according to a press release.

Eyenovia’s MicroProst, a treatment candidate for chronic angle closure glaucoma, open-angle glaucoma and ocular hypertension, and its myopia treatment candidate MicroPine are both in phase 3 development.

Oppenheimer & Co. Inc. is the offering’s sole book-running manager, with Ladenburg Thalmann & Co. Inc. acting as lead manager, the release said.